

StemRIM Announces Patent Registration (JP) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Fatty Liver and Non-alcoholic Steatohepatitis

Osaka, Japan, December 17, 2025 – StemRIM Inc. (TSE:4599, President and CEO: Masatsune Okajima; “StemRIM” or “Company”) announces that a medical use patent for the "Regeneration-Inducing Medicine™" development candidate, Redasemtide, indicated for fatty liver and non-alcoholic steatohepatitis, will soon be registered in Japan.

Title of Invention : Therapeutic drug for fatty liver and non-alcoholic steatohepatitis
Region : Japan
Application No. : 2023-550943
Registration No. : To be determined
Applicant : StemRIM Inc., Osaka University, Niigata University

This patent is intended to expand the indications for Redasemtide, which is currently under development, and we believe that the granting of this patent will ensure the possibility of developing a drug for fatty liver and non-alcoholic steatohepatitis in Japan.

Fatty liver is a condition in which excess fat accumulates in the liver. It is often asymptomatic and is associated with lifestyle-related diseases. Non-alcoholic steatohepatitis (NASH) is a progressive fatty liver disease caused by factors other than alcohol consumption characterized by inflammation and fibrosis of the liver, which, if left untreated, can lead to cirrhosis or liver cancer. Both fatty liver and NASH are expected to see an increase in patient numbers due to the rising prevalence of obesity and diabetes. However, there are currently no effective drug treatments available, and dietary and exercise therapy remain the main approaches. The development of new therapeutic drugs and regenerative medicine is urgently needed.

The impact on the financial performance for the fiscal year ending July 31, 2026, is insignificant. We will promptly disclose any additional information that needs to be disclosed.

* The terms "fatty liver" and "non-alcoholic steatohepatitis (NASH)" have been renamed to "steatotic liver disease (SLD)" and "metabolic dysfunction associated steatohepatitis (MASH)," respectively. However, in this press release, we have adopted the terminology used at the time of the patent application.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with ectomesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.

Management & Administrator Dept.

E-Mail: stemrim-ir@stemrim.com

X: [@StemRIM_Inc](#)

For more information, please visit the StemRIM website (<https://stemrim.com/english/>)